Chiltern inks a deal with Karolinska Development

CRO Chiltern has hooked up with Karolinska Development, signing on to run clinical trials for the group's many projects. Karolinska works to select and develop promising assets, then either sells or outlicenses them at a profit. Chiltern was chosen after an extensive CRO selection process, according to the company, and will lend its more than 30 years of trial experience. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.